Leizaola-Cardesa IO, Aguilar-Salvatierra A, Gonzalez-Jaranay M, Moreu G, Sala-Romero MJ, Gmez-Moreno G. Bisphosphonates, vitaminD, parathyroid hormone, and osteonecrosis of the jaw. Could there be a missing link?. Med Oral Patol Oral Cir Bucal. 2016 Mar 1;21 (2):e236-40. 

 

 

doi:10.4317/medoral.20927

http://dx.doi.org/doi:10.4317/medoral.20927

 

 

1. Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Impl Res. 2009;20:87-95.
http://dx.doi.org/10.1111/j.1600-0501.2009.01772.x

 

2. Sanz M, Naert I. Working Group 2. Biomechanics/risk management (Working Group 2). Clin Oral Impl Res. 2009;20:107-11.
http://dx.doi.org/10.1111/j.1600-0501.2009.01780.x

 

3. Sahota O. Osteoporosis and the role of vitamin D and calcium-vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency. Age Ageing. 2000;29:301-4.
http://dx.doi.org/10.1093/ageing/29.4.301

 

4. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40:1434-46.
http://dx.doi.org/10.1016/j.bone.2007.03.017

 

5. Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest. 2012;122:1803-15.
http://dx.doi.org/10.1172/JCI45890

 

6. Need AG, O'Loughlin PD, Morris HA, Coates PS, Horowitz M, Nordin BE. Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res. 2008;23:1859-63.
http://dx.doi.org/10.1359/jbmr.080607

 

7. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.
http://dx.doi.org/10.1210/edrv.22.4.0437

 

8. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, et al. Extrarenal expression of 25-hydroxyvitamin d (3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86:888-94.

 

9. White JH. Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun. 2008;76:3837-43.
http://dx.doi.org/10.1128/IAI.00353-08

 

10. Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, et al. A Global Study of Vitamin D Status and Parathyroid Function in Postmenopausal Women with Osteoporosis: Baseline Data from the Multiple Outcomes of Raloxifene Evaluation Clinical Trial. J Clin Endocrinol Metab. 2001;86:1212-21.
http://dx.doi.org/10.1210/jcem.86.3.7327

 

11. Thumbigere-Math V, Gopalakrishnan R, Michalowicz BS. Teriparatide Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw: A Case Report and Narrative. Review Northwest Dent. 2013;92:12-8.

 

12. Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?. Ann Oncol. 2006;17:1336-7.
http://dx.doi.org/10.1093/annonc/mdl045

 

13. Kim JW, Kong KA, Kim SJ, Choi SK, Cha IH, Kim MR. Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone. 2013;57:201-5.
http://dx.doi.org/10.1016/j.bone.2013.08.005

 

14. Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg. 2010;68:2241-7.
http://dx.doi.org/10.1016/j.joms.2010.05.043

 

15. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, et al. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg. 2009;67:159-61.
http://dx.doi.org/10.1016/j.joms.2008.09.015

 

16. Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol. 1996;51:145-7.
http://dx.doi.org/10.1007/s002280050175

 

17. Coin A, Veronese N, Bolzetta F, De Rui M, Manzato E, Sergi G. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates. Panminerva Med. 2012;54:277-82.

 

18. Greenspan SL, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan W, et al. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Physicians. 1996;108:230-8.

 

19. Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW, et al. Increased Prevalence of Bisphosphonate-Related Osteonecrosis of the Jaw with Vitamin D Deficiency in Rats. J Bone Miner Res. 2010;25:1337-49.
http://dx.doi.org/10.1002/jbmr.23

 

20. Bedogni A, Saia G, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Osteomalacia: The Missing Link in the Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaws?. Oncologist. 2012;17:1114-9.
http://dx.doi.org/10.1634/theoncologist.2012-0141

 

21. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-52.
http://dx.doi.org/10.1001/jama.282.14.1344

 

22. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91.
http://dx.doi.org/10.1007/s001980050010

 

23. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-40.
http://dx.doi.org/10.1056/NEJM200102013440503

 

24. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-9.
http://dx.doi.org/10.1359/JBMR.040325

 

25. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22.
http://dx.doi.org/10.1056/NEJMoa067312

 

26. Schussheim DH, Jacobs TP, Silverberg SJ. Hypocalcemia associated with alendronate. Ann Intern Med. 1999;130:329.
http://dx.doi.org/10.7326/0003-4819-130-4-199902160-00008

 

27. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med. 2003;348:1503-4.
http://dx.doi.org/10.1056/NEJM200304103481521

 

28. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract. 2006;12:48-53.
http://dx.doi.org/10.4158/EP.12.1.48

 

29. Diniz-Freitas M, Fernndez-Feijoo J, Fernndez-Montenegro P, Gonzlez-Mosquera A, Vzquez-Garca E, Diz-Dios P. Criteria for the prescription of oral bisphosphonates for the treatment of osteoporosis in a series of women referred for tooth extraction. Med Oral Patol Oral Cir Bucal. 2012;17:601-4.
http://dx.doi.org/10.4317/medoral.17681

 

30. Gmez-Moreno G, Arribas-Fernndez MC, Fernndez-Guerrero M, Boquete-Castro A, Aguilar-Salvatierra A, Guardia J, et al. Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment. Eur Rev Med Pharmacol Sci. 2014;18:1391-7.